Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations
Expert Review of Clinical Pharmacology · 2025
DOI: 10.1080/17512433.2025.2594496 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Eric Snoeck und 6 weiteren Autor:innen. Beteiligte Einrichtung: Luccio bv, Retie, Belgium. Hauptthemen laut MEDLINE: Paliperidone Palmitate, Receptors, Dopamine D2, Risperidone, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Laboratorios Farmacéuticos ROVI, S.A, Nicolas Luyckx is paid consultant of ROVI, Ibon Gutierro is employee of Laboratorios Farmacéuticos ROVI, S.A., the sole developer of Risperidone ISM®.
Abstract (Originalsprache)
BACKGROUND: Risperidone ISM® does not require loading dose or oral supplementation. Dopamine D2 Receptor Occupancy (D2RO) profiles between Risperidone ISM® versus oral risperidone (OR) and monthly paliperidone palmitate (PP1M) were compared. METHODS: D2RO time profiles were simulated using population pharmacokinetic models in conjunction with an Emax model relating D2RO with plasma levels. RESULTS: The median time
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Luccio bv, Retie, Belgium.
- Calvagone SAS, Chazay d'Azergues, France.
- Research and Development Department, Laboratorios Farmacéuticos ROVI, S.A., Madrid, Spain.
- Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Madrid, Spain.
Förderung
- Laboratorios Farmacéuticos ROVI, S.A
- Nicolas Luyckx is paid consultant of ROVI
- Ibon Gutierro is employee of Laboratorios Farmacéuticos ROVI, S.A., the sole developer of Risperidone ISM®
- Lourdes Anta is an employee of Laboratorios Farmacéuticos ROVI, S.A., the sole developer of Risperidone ISM®
- Eric Snoeck is paid consultant of ROVI
- Andreas Lindauer is paid consultant of ROVI
- Lourdes Ochoa Díaz de Monasterioguren is employee of Laboratorios Farmacéuticos ROVI, S.A., the sole developer of Risperidone ISM®
- Javier Martinez is employee of Laboratorios Farmacéuticos ROVI, S.A., the sole developer of Risperidone ISM®
Zitieren
APA
Snoeck, E., Luyckx, N., Lindauer, A., Ochoa Díaz de Monasterioguren, L., Anta, L., Martínez-González, J., & Gutierro, I. (2025). Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2594496
Vancouver
Snoeck E, Luyckx N, Lindauer A, Ochoa Díaz de Monasterioguren L, Anta L, Martínez-González J, et al. Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2594496
BibTeX
@article{Snoeck2025,
author = {Snoeck, Eric and Luyckx, Nicolas and Lindauer, Andreas and Ochoa Díaz de Monasterioguren, Lourdes and Anta, Lourdes and Martínez-González, Javier and Gutierro, Ibón},
title = {Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
doi = {10.1080/17512433.2025.2594496}
}
EUVIMED